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Airway remodelingAirway diseases such as asthma, emphysema, and chronic bronchitis are, in part, characterized by reversible
airﬂow obstruction and inﬂammation. In severe disease, marked decreases in lung function are associated
with airway smooth muscle proliferation and airway neutrophilia. Inhaled glucocorticoids attenuate in-
creased airﬂow obstruction and airway inﬂammation that occur, in part, due to increased smooth muscle mi-
gration and proliferation, as well as the airway neutrophilia. Glucocorticoids, however, have adverse side
effects and, in some patients, are ineffective despite high doses. Recent research has explored the effects
of non-traditional steroids on attenuation of inﬂammation associated with airway diseases. These
non-traditional steroids have improved side effect proﬁles in comparison to glucocorticoid therapy. Our stud-
ies assessed effects of dehydroepiandrosterone-3-sulfate (DHEA-S) on migration of both human peripheral
blood neutrophils (PMN) and human airway smooth muscle cells (HASM). DHEA-S dose-dependently
inhibited chemotaxis of PMN and HASM while having no effect on the phosphorylation levels of Akt, ERK1/
2, p38 MAPK or PKC, canonical positive regulators of cell migration. These studies demonstrate direct effects
of DHEA-S on cell migration, thereby suggesting that DHEA-S may attenuate airway inﬂammation and cell
migration.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Asthma and other airway diseases are marked by inﬂammation of
the airways, increased migration of airway smooth muscle cells, and
inﬂammatory cell inﬂux that contribute to airway remodeling. Cur-
rent therapeutics that modulate these responses traditionally com-
prise glucocorticoids and β2 adrenergic receptor (β2AR) agonists.
Unfortunately, some patients exhibit steroid insensitivity despite
high doses of glucocorticoids.
Dehydroepiandrosterone-3-sulfate (DHEA-S) and its metabolite
dehydroepiandrosterone (DHEA) are metabolites of cholesterol
that can be further metabolized into testosterone and estradiol. Evi-
dence suggests that levels of DHEA and DHEA-S in patients with
asthma are decreased, both in the stable phase of the disease as
well as during exacerbations [1]. Research in animal models and in125 South 31st Street, TRL Suite
3 9860; fax: +1 215 746 1224.
.J. Koziol-White),
uan@mail.med.upenn.edu
ya), rap@mail.med.upenn.edu
l rights reserved.clinical trials has demonstrated that DHEA-S and DHEA are effective
in attenuating Th2 cytokines associated with allergic disease, cyto-
kine elaboration and by inhibiting inﬂux of inﬂammatory cells into
the airways [2–4]. Therefore, supplementation of these naturally oc-
curring steroids may be therapeutically beneﬁcial and offer a
steroid-based therapy without the adverse side effects observed
with traditional glucocorticoid treatments. Although evidence sup-
ports the existence of both cell surface and nuclear receptors that
bind DHEA [5–7], the signaling pathways by which DHEA or
DHEA-S mediates its effects remain unclear.
We sought to determine the effects of DHEA-S on cells known to
be involved in the pathogenesis of asthma and COPD, human airway
smooth muscle cells (HASM) and primary human neutrophils
(PMN). We found that treatment with DHEA-S inhibited che-
mokinesis and chemotaxis of PMN, and chemokinesis of HASM. To
identify a mechanism by which DHEA-S inhibits cell migration, phos-
phorylation of Akt, ERK1/2, p38 MAPK and PKC were examined.
2. Methods
2.1. Neutrophil chemokinesis/chemotaxis
Peripheral blood (20–30 ml) was drawn from healthy donors, in
accordance with the Declaration of Helsinki and approved by the
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Fig. 1. DHEA-S inhibits neutrophil chemokinesis. Human peripheral blood neutrophils
were incubated with 0.01–10 μMDHEA-S, 0.01 μM roﬂumilast or 1 μMdexamethasone
for 4 h, transferred to transwell inserts and allowed to migrate in the absence of
chemoattractant. Data is represenatative of 3 separate experiments with triplicate
measurement of each condition. (* pb0.0001 compared to unstimulated control).
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Pennsylvania, layered over PMN isolation medium (Matrix) and
spun at room temperature for 35 min at 1500 rpm. The plasma and
mononuclear layers as well as half of the clear dextrose layer were as-
pirated off, and an equal volume of 0.45% NaCl was added, ﬁlling the
remaining volume with 0.9% NaCl. The resulting solution was cen-
trifuged for 15 min at 1500 rpm at room temperature. Supernatant
was removed, and the pellet was resuspended in 0.2% NaCl, and an
equal volume of 1.6% NaCl was added to ensure red blood cell lysis.
The solution was centrifuged at 1500 rpm for 15 min, supernatant re-
moved, and PMNs resuspended in media. Total number of cells was
counted, and 100,000 cells were incubated with DHEA-S (Epi-12323,
Epigenesis Pharmaceuticals, Cranbury, NJ) (0.01–10 μM) for 4 h prior
to loading into 12-well transwell plates with or without 10 nM fMLP
in the bottom chamber. Chemokinesis and chemotaxis were measured
by counting the number of cells present in the bottom chamber 2 h
after their addition onto the transwell insert. Cell viability was assessed
by trypan blue exclusion and caspase activation. A single concentration
of DHEA-S (10 μM) was chosen as the concentration to use for subse-
quent migration and signaling experiments, which was based on the
dose responses performed in the neutrophils but also as a result of
this concentration being used in clinical trials [3].
2.2. Human airway smooth muscle cell isolation and migration analysis
HASM cells were dissociated from human tracheas obtained from
human lung transplant donors, in accordance with the Declaration of
Helsinki and approved by the Committee on Studies Involving
Human Beings at the University of Pennsylvania, as described previ-
ously [8]. Cells derived from a minimum of two healthy donors were
cultured in Ham's F12 media (Life Technologies, Grand Island, NY),
supplemented with 10% FBS (HyClone Laboratories, Logan, UT),
100 U/ml penicillin, and 0.1 mg/ml streptomycin. Before the experi-
ments, HASM cells were maintained for 48 h in serum-free Ham's
F12 media, supplemented with 0.1% BSA. Cell migration was exam-
ined using a Boyden chamber apparatus as we described previously
[9]. Brieﬂy, HASM cells, pre-incubated with 10 μMDHEA-S or diluent
for 18 h, were brieﬂy trypsinized by 0.05% trypsin/0.53 mM EDTA,
centrifuged at 900 rpm for 10 min and resuspended in serum-free
media supplemented with BSA. Cells were then placed into the
upper wells of the Boyden chamber (5×104 cells/well) ﬁtted with
an 8-μm pore membrane coated with Vitrogen (100 μg/ml). Vehicle
or 10 ng/ml PDGF-BB in serum-free media supplemented with BSA
was added to the lower chambers. Cells in the Boyden chamber
were incubated for 4 h at 37 °C in a 5% CO2 incubator. Non-
migrated cells were scraped off, the membrane was ﬁxed with
methanol, stained with Hemacolor stain set (EM Industries, Inc.,
Gibbstown, NJ) and scanned. Cell migration was analyzed using the
Gel-Pro analyzer program (Media Cybernetics, Silver Spring, MD).
Cell viability was measured by trypan blue exclusion and caspase
activation.
2.3. Cell lysate preparation and immunoblot analysis
HASM cells were cultured in Ham's F12 media, supplemented
with 10% FBS, and primocin™ (Invivogen, San Diego, CA). Before
the experiments, HASM cells were maintained for 48 h in serum-free
Ham's F12 media, supplemented with 0.1% BSA. Cells were incubated
for 18 h with 10 μM DHEA-S, 1 μM dexamethasone (Sigma Aldrich, St.
Louis, MO), or for 40 min with 30 μM LY294002 (Cayman Chemicals,
Ann Arbor, MI), treated with 10 ng/ml PDGF-BB or diluent for 10 min,
and cell lysates were prepared as we described previously [10]. Cells
were also stimulated with PDGF (1 ng/ml) for 2, 5 or 30 min in the
presence and absence of 10 μM DHEA-S. Immunoblot analysis with
anti-phospho-Akt, anti-phospho ERK1/2, anti-phospho p38 MAPK,anti-phospho PKC and anti-COX-4 (Cell Signaling Technology, Danvers,
MA) was performed similarly as described [11].
2.4. Data analysis
Data points from individual assays represent mean values±standard
error. Statistically signiﬁcant differences among groups were assessed
with the analysis of variance (ANOVA) (with the Bonferroni–Dunn
correction), with values of Pb0.05 sufﬁcient to reject the null hypothesis
for all analyses. All experimentswere designedwithmatched control con-
ditions within each experiment to enable statistical comparison as paired
samples and to obtain statistically signiﬁcant data.
3. Results
3.1. DHEA-S inhibits PDGF-induced migration of human airway smooth
muscle cells (HASM)
To determine whether DHEA-S modulates migration of peripheral
blood neutrophils (PMN), we evaluated chemokinesis and fMLP-
induced chemotaxis of human primary PMN. Cells were incubated for
4 h with 0.01–10 μM DHEA-S, 0.01–10 μM roﬂumilast (a selective
phosphodiesterase 4 inhibitor), or 1 μM dexamethasone, and then
PMN migration was assessed in the presence or absence of 10 nM
fMLP. As seen in Fig. 1, DHEA-S, roﬂumilast and dexamethasone signif-
icantly inhibited PMN chemokinesis. Stimulation with fMLP induced a
~13-fold increase in PMN migration compared to diluent-treated cells
(Fig. 2A). Chemotaxis to fMLP was signiﬁcantly attenuated by pre-
incubation with 0.1, 1, and 10 μM DHEA-S, 1 and 10 μM roﬂumilast,
and 1 μM dexamethasone (Fig. 2B). Treatment with DHEA-S did not
affect PMN viability (data not shown). Taken together, these data sug-
gest that DHEA-S is effective at attenuating both chemokinesis and
fMLP-induced chemotaxis.
3.2. DHEA-S inhibits PDGF-induced migration of human airway smooth
muscle cells (HASM)
To evaluate effects of DHEA-S on HASM cell migration, cells were
pre-incubated for 18 h with DHEA-S, and then migration of HASM
in the presence or absence of PDGF was examined. We found that
DHEA-S had little effect on HASM cell chemokinesis (Fig. 3). PDGF
increased migration of HASM three-old over basal, and pretreatment
with DHEA-S signiﬁcantly reduced PDGF-induced HASM migration
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Fig. 2. DHEA-S inhibits fMLP-induced neutrophil migration. Human peripheral blood
neutrophils were incubated with 0.01–10 μM DHEA-S, 0.01 μM roﬂumilast or 1 μM
dexamethasone for 4 h, transferred to transwell inserts and allowed to migrate in the
presence of 10 nM fMLP for 2 h (A) and (B). Inhibition by treatment with compounds
(B) was expressed as a percentage of fMLP stimulated alone (set at 100%). Data is rep-
resentative of three to seven measurements per condition tested (*pb0.0001).
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Fig. 3. DHEA-S inhibits PDGF-mediated airway smooth muscle migration. HASM cells
were incubated with 10 μM DHEA-S overnight (18 h), loaded into a Boyden chamber
and allowed to migrate to 10 ng/ml PDGF for 4 h. Data is representative of triplicate
measurements from two different cell lines (*pb0.005).
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taxis, but not chemokinesis of HASM cells.3.3. DHEA-S has no effect on PDGF-induced Akt, ERK1/2, p38 MAPK and
PKC phosphorylation
To delineate potential mechanisms whereby DHEA-S attenuates
migration of HASM following PDGF stimulation, we ﬁrst assessed phos-
phorylation of Akt as a downstream substrate for PI3 kinase activation.
Previously, we reported that PI3 kinase (PI3K) activity is required for
PDGF-inducedHASMmigration byutilizing the pharmacological inhibitor
LY294002 to inhibit PI3K [11]. We reasoned that DHEA-S alters PI3K-Akt
signaling pathways to decrease PDGF-induced migration of HASM. We
found that pretreatment of HASM with 10 μM DHEA-S or 1 μM dexa-
methasone, which inhibited PDGF-induced HASM migration (Fig. 3 and
[9]), has little effect on PDGF-induced phosphorylation of Akt. Pre-
treatment with PI3K inhibitor LY294002 under similar experimental
conditions suppressed Akt phosphorylation (Fig. 4A and B). The phos-
phorylation state of other signalingmolecules known to positivelymodu-
late cellular migration, including ERK1/2, p38 MAPK and PKCα were
examined to assess a potential role for these in DHEA-S-mediated attenu-
ation of PDGF-induced migration (Fig. 4A–D). The phosphorylation of all
proteins tested was unaffected by pretreatment with DHEA-S and subse-
quent stimulation with PDGF. These data suggest that DHEA-S inhibits
PDGF-mediated HASM migration independently of canonical pathways
known to regulate migration.4. Discussion
In this study, we sought to examine the effects of DHEA-S on mi-
gration of human neutrophils (PMNs) and airway smooth muscle
cells (HASM). We found that DHEA-S dose-dependently decreased
chemokinesis and fMLP-induced chemotaxis of PMNs, as well as
PDGF-mediated chemotaxis of HASM. Two types of commonly used
asthma and COPD therapeutics were used as comparison since dexa-
methasone, a glucocorticoid, and roﬂumilast, a phosphodiesterase 4
inhibitor, inhibit PDGF-induced airway smoothmuscle migration [9].
We show that at 10 μM, but not at lower concentrations, roﬂumilast is
more effective than DHEA-S at inhibiting fMLP-induced chemotaxis.
Given these dose responses, we show that roﬂumilast is more potent
and effective at similar concentrations of DHEA-S. In an effort to elucidate
potentialmechanisms for DHEA-S-mediated attenuation ofmigration,we
assessed Akt phosphorylation, a surrogate for PI3K activation, as well as
ERK1/2, p38 MAPK and PKCα phosphorylation — signaling molecules
known to modulate cell migration. We found that treatment with
DHEA-S had little effect on PDGF-mediated Akt, ERK1/2, p38 MAPK and
PKCα phosphorylation. Interestingly, a study of vascular smooth muscle
demonstrated thatDHEA inhibited phosphorylation of Akt at a concentra-
tion ten-fold higher than we utilized to inhibit cell migration [12], a ﬁnd-
ing that contrasts with effect of DHEA-S that we show. Our data suggests
that othermechanisms governing cytoskeletal rearrangements necessary
for coordinated cell movement are affected and attenuated by DHEA-S
treatment, rather than canonical pathways governing cell migration.
Glucocorticoids, a mainstay in the treatment of lung disorders,
decrease airway inﬂammation in asthma and COPD. Although effective
at reducing inﬂammation, steroids have undesirable effects, and somepa-
tients are insensitive to glucocorticoids. Use of anti-inﬂammatory alterna-
tives exhibiting fewer adverse effects may serve as alternative strategies.
DHEA and DHEA-S offer potential options to traditional glucocorticoid
therapy. Inmice, OVA-induced allergic airway inﬂammationwasmarked-
ly attenuated by DHEA-S, and this treatment decreased eosinophilic inﬁl-
tration of the lungs as well as inhibited increases in eotaxin-1 and
eotaxin-2, IL-5, IL-13, IL-6 and TNFα expression. Interestingly, DHEA
treatment also decreased levels of PGE2 [2]. Collectively, these data
suggest that DHEA-S can attenuate cytokine-induced hyper-
responsiveness of airway smooth muscle, but may increase the
agonist-mediated bronchoconstriction by decreasing endogenous
levels of PGE2. Others showed, using Der f, a house dust mite allergen,
eosinophil inﬂux, and IL-4 and IL-5 levels into the lungs were
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Fig. 4. DHEA-S does not inhibit PDGF-dependent phosphorylation of Akt, ERK1/2, p38 MAPK or PKC. (A–B) HASM cells were incubated with 10 μM DHEA-S (18 h), 1 μM dexameth-
asone (18 h) or 30 μM LY294002 (40 min) prior to stimulation with 1 ng/ml PDGF (10 min). Phosphorylation of Akt and ERK1/2 was assessed by immunoblotting. Total COX-4 was
used as a loading control. (C–D) HASM cells were incubated with 10 μM DHEA-S (18 h) prior to stimulation with 1 ng/ml PDGF (2, 5 and 30 min). Phosphorylation of Akt, ERK1/2,
p38 MAPK, and PKC was assessed, using total COX-4 as a loading control. Data is representative of three independent experiments in three different cell lines.
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data suggest that DHEA and DHEA-S maymodulate inﬂammatory re-
sponses associated with allergen-induced airway diseases. In human
studies, nebulized DHEA and DHEA-S attenuated allergen-induced
late phase response in mild asthma subjects [3]. Using human
PBMCs, DHEA also decreased IL-10, IL-5 and IFNγ production, and
this decreased cytokine production was more pronounced in indi-
viduals exhibiting airway hyperresponsiveness [13].
Radford et al. demonstrated that treatment of human neutrophils
with DHEA-S increased superoxide formation, in both the presence and
absence of priming with GM-CSF [14]. Others, utilizing neutrophils and
endothelial cells, showed that DHEA treatment increased L-selectin ex-
pression, decreased LPS-induced CD11b expression, and had little effect
on CD18 expression in neutrophils. On endothelial cells, there was also
little effect on LPS-induced levels of VCAM or ICAM-1 expression. Levels
of E-selectin, however, were decreased following DHEA alone or in com-
bination with LPS stimulation [15]. In rat tracheal smooth muscle, DHEA
treatment decreased proliferation of the smoothmuscle following stimu-
lation with FBS or PDGF [16]. Utilizing a rabbit vascular smooth muscle
cell line, Furutama et al. demonstrated that DHEA-S administration
inhibited PDGF-induced cell migration, proliferation and adhesion to ﬁ-
bronectin [5]. This same study noted using Scatchard analysis that a ma-
jority of DHEA-Swas found to be bound in the nucleus, suggesting that it
is indeed binding a nuclear receptor. Given current evidence, we hypoth-
esized that DHEA-S may have direct effects on neutrophils and HASM
that modulate inﬂammation observed in asthma. We found that treat-
ment of human neutrophils with DHEA-S inhibited both chemotaxis
and chemokinesis of the cells. In animal studies, DHEA-S inhibited im-
mune cell recruitment to the lungs following allergen challenge. Our
data also suggest that the effects of DHEA-S may not be exclusively afunction of decreasing levels of inﬂammatory mediators necessary to re-
cruit cells, butmay alsomodulate cytoskeletal arrangementswithin cells.
Wedemonstrated thatmigration ofHASMto the growth factor PDGFwas
also inhibited by DHEA-S, suggesting a generalized effect of DHEA-S on
cell migration. We also showed that a dose of DHEA-S that inhibited mi-
gration had little effect on PDGF-induced phosphorylation of Akt, which
is a downstream substrate of PI3K that is required for PDGF-mediated
HASM migration [11]. The effect of DHEA-S on phosphorylation of
ERK1/2, p38 MAPK and PKCαwas examined as other potential signaling
molecules modulating cell migration. A study examining migration of
neutrophils to fMLP noted that inhibition of myristoylated alanine-rich
c-kinase substrate (MARCKS), a target of PKCα in addition to ERK1/2
and p38MAPK, abolished chemokine-dependent migration [17]. We ex-
amined phosphorylation of PKCα in our study and found that there was
nomodulation of phosphorylation of thesemolecules. Further studies are
necessary to deﬁne the probable mechanism by which DHEA-S attenu-
ates cell migration; we speculate that DHEA-S directly modulates cyto-
skeletal rearrangements. Collectively, DHEA-S may have beneﬁt in the
treatment of airway disorders such as asthma and COPD, not only by
inhibiting inﬂammatory mediator secretion but also by inhibiting
myocyte and immune cell migration.Role of funding source
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